This review provides an up-to-date overview of coatings for cardiovascular stents, focusing on both organic and inorganic materials. Cardiovascular diseases (CVDs) are a significant global health burden, and the use of stents, particularly drug-eluting stents (DESs), has become a standard treatment for coronary artery disease. However, DESs face challenges such as in-stent restenosis, delayed endothelialization, and sub-acute stent thrombosis. The effectiveness of DESs depends on various factors, including polymer degradability, drug release profiles, stent platforms, and the metals used in the stents. Organic coatings, such as synthetic and natural polymers, direct drug coating, and endothelial cell coatings, are designed to enhance biocompatibility, reduce inflammation, and promote endothelialization. Synthetic polymers like poly(ethylene-co-vinyl acetate) (PEVA) and poly(n-butyl methacrylate) (PBMA) have been used in early-generation DESs, but newer biocompatible polymers with lower inflammatory responses have been developed. Natural polymers like chitosan, heparin, hyaluronic acid, and fibrin offer unique properties such as antibacterial and anticoagulant effects. Biodegradable polymers, such as poly(L-lactic acid) (PLLA) and poly(glycolic acid) (PGA), are also being explored for their ability to reduce stent-related side effects. Inorganic coatings, including metallic and non-metallic materials, aim to improve stent performance and reduce complications. Titanium-based coatings, such as TiOxNy, enhance biocompatibility, reduce platelet adhesion, and improve corrosion resistance. Non-metallic coatings, like phosphate-based and fluoride-based coatings, are also being investigated for their potential benefits. The review highlights the advancements in stent coatings and their impact on clinical outcomes, emphasizing the need for further research to optimize these coatings for better patient outcomes.This review provides an up-to-date overview of coatings for cardiovascular stents, focusing on both organic and inorganic materials. Cardiovascular diseases (CVDs) are a significant global health burden, and the use of stents, particularly drug-eluting stents (DESs), has become a standard treatment for coronary artery disease. However, DESs face challenges such as in-stent restenosis, delayed endothelialization, and sub-acute stent thrombosis. The effectiveness of DESs depends on various factors, including polymer degradability, drug release profiles, stent platforms, and the metals used in the stents. Organic coatings, such as synthetic and natural polymers, direct drug coating, and endothelial cell coatings, are designed to enhance biocompatibility, reduce inflammation, and promote endothelialization. Synthetic polymers like poly(ethylene-co-vinyl acetate) (PEVA) and poly(n-butyl methacrylate) (PBMA) have been used in early-generation DESs, but newer biocompatible polymers with lower inflammatory responses have been developed. Natural polymers like chitosan, heparin, hyaluronic acid, and fibrin offer unique properties such as antibacterial and anticoagulant effects. Biodegradable polymers, such as poly(L-lactic acid) (PLLA) and poly(glycolic acid) (PGA), are also being explored for their ability to reduce stent-related side effects. Inorganic coatings, including metallic and non-metallic materials, aim to improve stent performance and reduce complications. Titanium-based coatings, such as TiOxNy, enhance biocompatibility, reduce platelet adhesion, and improve corrosion resistance. Non-metallic coatings, like phosphate-based and fluoride-based coatings, are also being investigated for their potential benefits. The review highlights the advancements in stent coatings and their impact on clinical outcomes, emphasizing the need for further research to optimize these coatings for better patient outcomes.